Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
Full approval will depend on verification of clinical benefit in a confirmatory trial
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Subscribe To Our Newsletter & Stay Updated